PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Advanced Accelerator Applications Announces European Approval of Lutathera® for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumours

Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA), an international specialist in Molecular Nuclear Medicine (MNM), announced that the European Commission (EC) has approved the marketing authorisation of Lutathera® (lutetium (177Lu) oxodotreotide) for “the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.”
This approval allows for the marketing of Lutathera® in all 28 European Union member states, as well as Iceland, Norway and Liechtenstein.
Stefano Buono, Chief Executive Officer of AAA, commented: “This is a historic moment for the company. We are proud to bring this first-in-class drug, and the very first registered Peptide Receptor Radionuclide Therapy (PRRT), to the European NET patient community. We will continue to work closely with the respective health authorities in each country to make Lutathera® widely available. Numerous clinical studies in the nuclear medicine field have demonstrated the advantages of selectively delivering radiation to tumour cells over certain other therapies, and we are committed to advancing this approach to cancer treatment. “
“With this approval, AAA has become the first theragnostic radiopharmaceutical company in the oncology market. We believe our platform, which involves radiolabeling a single targeting molecule with either gallium Ga 68 for diagnostic use or lutetium Lu 177 for therapeutic use will deliver improved patient outcomes”, Buono added.
Martyn Caplin, Professor of gastroenterology and GI neuroendocrinology at the Royal Free London and University College London and Vice Chair (former Chairman) of the European Neuroendocrine Tumor Society, stated: “There are very few effective treatment options for patients with inoperable, advanced GEP-NETs who are progressive on somatostatin analogues. Having this therapy approved and available will offer physicians a further option to help manage their patients’ disease.”
 

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026